Susan Scott, MD

This concluding segment explores the future of EGFR-mutant non-small cell lung cancer (NSCLC) treatment beyond current osimertinib-based therapy.

This segment examines the real-world challenges of ensuring timely access to effective therapies for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

This segment explores treatment sequencing following progression on osimertinib-based therapy for EGFR-mutant non-small cell lung cancer (NSCLC).

This segment examines best practices for monitoring treatment response and evaluating disease progression during osimertinib-based therapy for EGFR-mutant non-small cell lung cancer (NSCLC).

This segment explores the evolving role of circulating tumor DNA (ctDNA) in monitoring treatment response in EGFR-mutant non-small cell lung cancer (NSCLC).

This segment focuses on the real-world management of treatment-related toxicities in EGFR-mutant non-small cell lung cancer (NSCLC).

This segment discusses the clinical impact of transitioning from intravenous to subcutaneous amivantamab in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC).

This segment compares the currently available frontline combination treatment options for EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing the importance of individualized treatment selection.

This segment examines treatment approaches following disease progression in EGFR-mutant non-small cell lung cancer (NSCLC), with a focus on the role of continuing osimertinib beyond progression.

This segment focuses on identifying clinical factors that influence the use of combination therapy for EGFR-mutant non-small cell lung cancer (NSCLC).

This segment explores how treatment decisions for EGFR-mutant non-small cell lung cancer (NSCLC) are increasingly individualized despite the availability of combination frontline therapies.

This introductory segment provides an overview of the evolving treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC) and establishes the key themes for the discussion.

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.